Prof. Matthew Rizzo

Dr. Matthew Rizzo
Afiliation
University of Nebraska, US
Bio
Dr. Matthew Rizzo is Chair of the Department of Neurological Sciences, Chief Physician for Neurological Services, Director of the Mind & Brain Health Initiative at the University of Nebraska Medical Center, and Director of the US National Institutes of Health funded Great Plains IDeA Clinical and Translational Research network. Dr. Rizzo has mentored many faculty and students who have established successful careers in science and medicine. Relevant service includes the US National Academy of Sciences Board on Human-Systems Integration, US FDA Panel for PNS and CNS Drugs, FMCSA Medical Advisory Committee (appointed by US Secretary of Transportation), and Chair of the Board of Directors of the American Brain Coalition. Dr. Rizzo has advised the US Army, AAN, AMA, and several US and international states on translational neuroscience and neuroegonomics research and evidence-based strategies for evaluating and supporting vulnerable operators. He has led efforts to improve and disseminate better simulation tools and practices and has helped pioneer successive generations of tools for naturalistic behavioral research in aging, cognitive impairments, and medical disorders in at-risk individuals. His team’s advancements in quantifying driver behavior from in-vehicle systems (“Black Boxes”) and wearable sensors, and strategic analytic pipelines using statistical and machine learning approaches, are directly relevant to meeting this challenge. A current focus of this silo-spanning “brain-in the wild” work is using sensors in a person’s own vehicle and devices as a passive-detection system for flagging age- and disease-related aberrant behavior and physiology (“digital biomarkers”) that may signal early warning signs of functional decline or incipient disease, such as Alzheimer’s. Passive monitoring of real-world physiology and behavior to predict clinical status in the moment, progression over time, and response to treatment, promotes global goals for early treatment and timely interventions to prevent disease progression in preclinical stages, and advance broader community access to healthcare.